Dual HER2 targeting with trastuzumab and liposomal-encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancer

Cancer Research

Volumn 76, Issue 6, 2016, Pages 1517-1527

  Espelin, Christopher W ^a   Leonard, Shannon C ^a   Geretti, Elena ^a   Wickham, Thomas J ^a   Hendriks, Bart S ^a  

^a MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOSOME; PROTEIN KINASE B; PROTEIN P53; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ERBB2 PROTEIN, HUMAN; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DNA DAMAGE; DRUG BINDING; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STOMACH CANCER; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DRUG EFFECTS; GENETICS; METABOLISM; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; POLYETHYLENE GLYCOLS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84962052506     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1518     Document Type: Article

References (47)

1. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014; 2014: 1-9.
2. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-84.
3. Wong DJ, Hurvitz SA. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Trans Med 2014; 2: 1-14.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
5. Eroglu Z, Tagawa T, Somlo G. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist 2014; 19: 135-50.
6. Gennari A, Pronzato P. New understanding of the role of anthracyclines in early-stage breast cancer patient selection considerations. Clin Breast Cancer 2008; 100: 14-20.
7. Kawachi K, Sasaki T, Murakami A, Ishikawa T, Kito A, Ota I, et al. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy. Pathol Res Pract 2010; 206: 156-62.
8. Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011; 7: 214-20.
9. Smith RE Risk for the development of treatment-related acute myelocytic leukemia and myelo-dysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer 2003; 4: 273-9.
10. Montemurro F, Rossi V, Nole F, Redana S, Donadio M, Martinello R, et al. Underuse of anthracyclines in women with HER-2+ advanced breast cancer. Oncologist 2010; 15: 665-72.
11. Giordano SH, Lin Y-L, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol 2012; 30: 2232-9.
12. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev 2015; 91: 3-6.
13. 2. Ann Oncol 2000; 11: 1029-33.
14. O'Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX /Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-9.
15. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002; 8: 1172-81.
16. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006; 66: 6732-40.
17. Hendriks BS, Klinz SG, Reynolds JG, Espelin CW, Gaddy DF, Wickham TJ. Impact of tumor HER2/ERBB2 expression level on HER2-targeted lipo-somal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect. Mol Cancer Ther 2013; 12: 1816-28.
18. Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol Appl Pharmacol 2012; 262: 1-10.
19. Onsum MD, Geretti E, Paragas V, Kudla AJ, Moulis SP, Luus L, et al. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. Am J Pathol 2013; 183: 1446-60.
20. Cho H-S, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421: 756-60.
21. Millard BL, Niepel M, Menden MP, Muhlich JL, Sorger PK. Adaptive informatics for multifactorial and high-content biological data. Nat Methods 2011; 8: 487-93.
22. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5: 2676-84.
23. Bliss C. The toxicity of poisons applied jointly. Ann Appl Biol 1939; 26: 585-615.
24. Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009; 53: 2382-91.
25. Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 2015; 3:e00149.
26. Seyedmousavi S, Brüggemann RJM, Melchers WJG, Rijs AJMM, Verweij PE, Mouton JW. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J Antimicrob Chemother 2013; 68: 385-93.
27. Pflaum J, Schlosser S, Muller M. p53 family and cellular stress responses in cancer. Front Oncol 2014; 4: 1-15.
28. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402.
29. Cole AJ, Priddee NR, McAleer JJ. Chemotherapy causes cancer!acase report of therapy related acute myeloid leukaemia in early stage breast cancer. Ulster Med J 2013; 82: 97-9.
30. Azim H, de Azambuja E, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 2011; 22: 1939-47.
31. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005; 23: 4179-91.
32. Felix C. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400: 233-55.
33. Ewer MS, Swain SM, Cardinale D, Fadol A, Suter TM. Cardiac dysfunction after cancer treatment. Texas Hear Inst J 2011; 38: 248-52.
34. Von Minckwitz G, Du Bois A, Schmidt M, Maass N, Cufer T, De Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009; 27: 1999-2006.
35. Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Ann Rev Med 2015; 66: 111-28.
36. Hudis C. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 35739-51.
37. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94: 259-67.
38. Jain RK Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014; 26: 605-22.
39. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-80.
40. Wen X-F, Yang G, Mao W, Thornton A, Liu J, Bast RC, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006; 25: 6986-96.
41. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-121.
42. McCormack DR, Walsh AJ, Sit W, Arteaga CL, Chen J, Cook RS, et al. In vivo hyperspectral imaging ofmicrovessel responsetotrastuzumab treatment in breast cancer xenografts. Cancer 2014; 5: 2247-61.
43. Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn J Clin Oncol 2009; 39: 756-66.
44. Verheul HMW, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-85.
45. Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011; 13:R46.
46. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011; 128: 347-56.
47. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100: 14-20.